S&P 500   3,306.10 (-1.52%)
DOW   27,564.70 (-1.21%)
QQQ   264.13 (-2.29%)
AAPL   107.01 (-3.02%)
MSFT   198.09 (-2.38%)
FB   251.36 (-1.36%)
GOOGL   1,438.25 (-3.28%)
AMZN   2,930.35 (-2.61%)
NVDA   482.45 (-3.23%)
TSLA   435.06 (+2.75%)
BABA   272.17 (-1.29%)
CGC   16.27 (-0.79%)
GE   6.90 (-2.13%)
MU   50.27 (-1.39%)
AMD   74.35 (-2.87%)
T   28.96 (-0.38%)
F   7.25 (-0.41%)
ACB   6.41 (-6.97%)
GILD   64.41 (-0.97%)
NFLX   461.62 (-1.82%)
DIS   128.70 (-1.17%)
BAC   25.28 (-0.28%)
BA   162.49 (-3.01%)
S&P 500   3,306.10 (-1.52%)
DOW   27,564.70 (-1.21%)
QQQ   264.13 (-2.29%)
AAPL   107.01 (-3.02%)
MSFT   198.09 (-2.38%)
FB   251.36 (-1.36%)
GOOGL   1,438.25 (-3.28%)
AMZN   2,930.35 (-2.61%)
NVDA   482.45 (-3.23%)
TSLA   435.06 (+2.75%)
BABA   272.17 (-1.29%)
CGC   16.27 (-0.79%)
GE   6.90 (-2.13%)
MU   50.27 (-1.39%)
AMD   74.35 (-2.87%)
T   28.96 (-0.38%)
F   7.25 (-0.41%)
ACB   6.41 (-6.97%)
GILD   64.41 (-0.97%)
NFLX   461.62 (-1.82%)
DIS   128.70 (-1.17%)
BAC   25.28 (-0.28%)
BA   162.49 (-3.01%)
S&P 500   3,306.10 (-1.52%)
DOW   27,564.70 (-1.21%)
QQQ   264.13 (-2.29%)
AAPL   107.01 (-3.02%)
MSFT   198.09 (-2.38%)
FB   251.36 (-1.36%)
GOOGL   1,438.25 (-3.28%)
AMZN   2,930.35 (-2.61%)
NVDA   482.45 (-3.23%)
TSLA   435.06 (+2.75%)
BABA   272.17 (-1.29%)
CGC   16.27 (-0.79%)
GE   6.90 (-2.13%)
MU   50.27 (-1.39%)
AMD   74.35 (-2.87%)
T   28.96 (-0.38%)
F   7.25 (-0.41%)
ACB   6.41 (-6.97%)
GILD   64.41 (-0.97%)
NFLX   461.62 (-1.82%)
DIS   128.70 (-1.17%)
BAC   25.28 (-0.28%)
BA   162.49 (-3.01%)
S&P 500   3,306.10 (-1.52%)
DOW   27,564.70 (-1.21%)
QQQ   264.13 (-2.29%)
AAPL   107.01 (-3.02%)
MSFT   198.09 (-2.38%)
FB   251.36 (-1.36%)
GOOGL   1,438.25 (-3.28%)
AMZN   2,930.35 (-2.61%)
NVDA   482.45 (-3.23%)
TSLA   435.06 (+2.75%)
BABA   272.17 (-1.29%)
CGC   16.27 (-0.79%)
GE   6.90 (-2.13%)
MU   50.27 (-1.39%)
AMD   74.35 (-2.87%)
T   28.96 (-0.38%)
F   7.25 (-0.41%)
ACB   6.41 (-6.97%)
GILD   64.41 (-0.97%)
NFLX   461.62 (-1.82%)
DIS   128.70 (-1.17%)
BAC   25.28 (-0.28%)
BA   162.49 (-3.01%)
Log in
NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$6.27
+0.11 (+1.79 %)
(As of 09/18/2020 01:44 PM ET)
Add
Compare
Today's Range
$6.21
Now: $6.27
$6.58
50-Day Range
$5.19
MA: $6.41
$9.01
52-Week Range
$4.20
Now: $6.27
$10.67
Volume13,461 shs
Average Volume235,026 shs
Market Capitalization$161.83 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More
Fennec Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.60 per share

Profitability

Net Income$-12,770,000.00

Miscellaneous

EmployeesN/A
Market Cap$161.83 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$6.27
+0.11 (+1.79 %)
(As of 09/18/2020 01:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

How has Fennec Pharmaceuticals' stock been impacted by COVID-19?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FENC stock has decreased by 4.1% and is now trading at $6.36.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fennec Pharmaceuticals
.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Fennec Pharmaceuticals
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.03.
View Fennec Pharmaceuticals' earnings history
.

What price target have analysts set for FENC?

3 Wall Street analysts have issued 12 month price targets for Fennec Pharmaceuticals' shares. Their forecasts range from $11.00 to $18.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals
.

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,180,000 shares, an increase of 11.3% from the August 15th total of 1,060,000 shares. Based on an average daily volume of 467,700 shares, the days-to-cover ratio is presently 2.5 days. Currently, 6.3% of the company's shares are short sold.
View Fennec Pharmaceuticals' Short Interest
.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Immunomedics (IMMU), AbbVie (ABBV), Amarin (AMRN), Iovance Biotherapeutics (IOVA), VBI Vaccines (VBIV) and Exelixis (EXEL).

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sonic Fund II L.P. (6.45%), Opaleye Management Inc. (0.67%), Cadence Capital Management LLC (0.61%), Nuveen Asset Management LLC (0.30%), Hartford Financial Management Inc. (0.20%) and Bank of New York Mellon Corp (0.19%).
View institutional ownership trends for Fennec Pharmaceuticals
.

Which major investors are buying Fennec Pharmaceuticals stock?

FENC stock was purchased by a variety of institutional investors in the last quarter, including Sonic Fund II L.P., Opaleye Management Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Bank of America Corp DE, Jane Street Group LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Fennec Pharmaceuticals
.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $6.36.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $164.15 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.